Agilis and Intrexon partner to develop DNA-based therapeutics for rare genetic disease

US-based synthetic biology companies Agilis Biotherapeutics and Intrexon have entered into an exclusive channel collaboration (ECC) agreement to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news